Coherus Oncology (CHRS) Profit After Tax (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Profit After Tax data on file, last reported at -$38.3 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 19.14% year-over-year to -$38.3 million; the trailing twelve-month figure through Mar 2026 stood at $186.3 million (up 150.94% YoY), and the FY2025 full-year result was $168.0 million, up 178.01% from the prior year.
• Profit After Tax fell to -$38.3 million in Q1 2026, from -$37.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $297.8 million in Q2 2025 to a low of -$294.6 million in Q4 2024.
• A 5-year average of -$35.7 million and a median of -$42.9 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 269.85% in 2024 and surged 2404.52% in 2025, its largest moves.
• Tracing CHRS's Profit After Tax over 5 years: stood at -$58.9 million in 2022, then sank by 35.3% to -$79.7 million in 2023, then plunged by 269.85% to -$294.6 million in 2024, then jumped by 87.22% to -$37.6 million in 2025, then fell by 1.82% to -$38.3 million in 2026.
• Business Quant data shows CHRS's Profit After Tax at -$38.3 million in Q1 2026, -$37.6 million in Q4 2025, and -$35.5 million in Q3 2025.